# Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

> **NCT02975557** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sandeep Jain, MD** · enrollment: 15 (actual)

## Conditions studied

- Dry Eye
- Ocular Graft vs Host Disease
- Meibomian Gland Dysfunction

## Interventions

- **DRUG:** Brimonidine 0.15%
- **DRUG:** Brimonidine 0.075%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02975557
- **Lead sponsor:** Sandeep Jain, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05
- **Primary completion:** 2017-04-13
- **Final completion:** 2017-04-13
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Slow accrual of subjects. May take longer than expected to complete the trial.
- **Last updated:** 2019-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975557, "Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02975557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*